(HOME) Subject: osteomalacia/iron
Endocr J 1998 Aug;45(4):431-9
Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy
due to nephropathy.
Sato K, Shiraki M
Department of Medicine, Institute of Clinical Endocrinology, Tokyo
Women's Medical College, Japan.
[Medline record in process]
Saccharaed ferric oxide (SFO)-induced osteomalacia develops when
excessive SFO infusions are administrated to patients with anemia for
prolonged periods for a few years. The small particles and almost
neutral saccharide of SFO filter through the glomerular tufts into the
renal tubules, resulting in impairment of proximal renal tubular
function, particularly renal reabsorption of phosphate and
1alpha-hydroxylase activity, resulting in decreased serum levels of
phosphorus and active vitamin D, both of which lead to development of
hypophosphatemic osteomalacia. Furthermore, SFO, at concentrations
attainable in serum, exacerbates the osteomalacia by inhibiting bone
formation directly. In contrast to itai-itai disease, another
iatrogenic osteomalacia due to cadmium nephropathy [44], the proximal
renal tubular function impairment induced by SFO is reversible simply
by discontinuing the nephrotoxin, which is followed by improvement of
all the clinical manifestations, except bone deformities. So far,
SFO-induced osteomalacia, that is, SFO-induced osteopathy due to
nephropathy, has been reported only in Japan, probably due to the lax
surveillance system of the health insurance scheme. All physicians who
prescribe SFO should be aware of its severe adverse effects. We hope
that such iatrogenic osteomalacia caused by abusive infusion of SFO
will never again be reported in our country.
PMID: 9881891, UI: 99096218
_________________________________________________________________
Save the above report in [Macintosh] [Text] format
Order documents on this page through Loansome Doc
_________________________________________________________________
(HOME)